Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A7 | Q9GZV3 | 3/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | WNT1 | P04628 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666647 | 0.86 | SLC5A7 (0.54) | SLC5A7KMT2ANPC1ROCK2MEN1 | |
| SCHEMBL4878514 | 0.84 | SLC5A7 (0.49) | SLC5A7AURKACHRM3NPC1ROCK2 | |
| SCHEMBL4664201 | 0.83 | MMP13 (0.55) | SLC5A7KMT2ANPC1APOBEC3AAPOBEC3G | |
| SCHEMBL4666649 | 0.82 | SLC5A7 (0.54) | SLC5A7KMT2ANPC1APOBEC3AAPOBEC3G | |
| SCHEMBL4666174 | 0.82 | ROCK2 (0.59) | SLC5A7CHRM3KMT2ANPC1APOBEC3A | |
| SCHEMBL4772536 | 0.82 | SLC5A7 (0.51) | SLC5A7CHRM3KMT2ANPC1APOBEC3A | |
| SCHEMBL14026963 | 0.82 | LMNA (0.64) | SLC5A7KMT2ANPC1APOBEC3AAPOBEC3G | |
| SCHEMBL4933296 | 0.81 | SLC5A7 (0.60) | SLC5A7CHRM3KMT2ANPC1APOBEC3A | |
| Hydrochloric Acid SCHEMBL4666207 | 0.81 | LMNA (0.63) | SLC5A7KMT2ANPC1APOBEC3AAPOBEC3G | |
| SCHEMBL4844944 | 0.80 | SLC5A7 (0.48) | SLC5A7KMT2ANPC1APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| EP-1891065-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006130075-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | claimed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1891065-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006130075-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | MCHR1, MCHR2, HCRTR1 | SLC5A7 854/4885AURKA 4058/4885CHRM3 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.